Compare IDEXX Laboratories, Inc. (IDXX) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JD.Com Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while JD.Com Inc trades at $31.65 (market cap $44.04B). The key difference: IDEXX Laboratories, Inc. and JD.Com Inc are close in size by market cap, and JD.Com Inc pays a 3.13% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | JD | |
|---|---|---|
Market Cap | $46.22B | $44.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $36.17 |
52-Week Low | $526.44 | $25.19 |
Enterprise Value | $47.12B | $30.10B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
JD.com trades at $31.46, down 6.01% over 24 hours, with technical indicators showing bullish momentum despite recent pressure. The company reported strong Q1 2026 earnings of $0.74 EPS, beating expectations by 30%, while revenue grew to $1.31 trillion in 2025. Analysts maintain a bullish consensus with 32 buy ratings and a $38.00 price target, representing 21% upside potential. Recent news highlights JD's upcoming Q2 earnings report on August 13, 2026, with expectations of 618 promotion benefits.
JD presents compelling value with a P/S ratio of 0.24 and consistent earnings beats, though net margins remain thin at 1.05%. Regulatory scrutiny of the Ceconomy acquisition and competitive pressures pose risks, but institutional accumulation and bullish technicals support further upside. The stock's current level near key support at $31 offers an attractive entry point ahead of Q2 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
